Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.
Aaron Waxman, MD, PhD
Advertisement
Aaron Waxman, MD, PhD, is the executive director of the Center for Pulmonary Heart Diseases at Brigham and Women’s Hospital.
Articles by Aaron Waxman, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
2
8 Endocrinology Headlines You Missed in Q3 2026
3
Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis
4
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
5